|

iNeo-Vac-R01 Clinical Trials

4 actively recruiting trials

Pipeline

Phase 1: 2Phase 1/2: 2

Top Sponsors

  • Sir Run Run Shaw Hospital2
  • Yinghua Xu1
  • Yifan Wang1

Indications

  • Cancer4
  • Digestive System Neoplasms2
  • Liver Disease1
  • Biliary Malignant Tumors1
  • Hepatocellular Carcinoma (HCC)1

Other4 trials

A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection
Phase 1/2
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms
Phase 1
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms
Phase 1
Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.